clinical trial · NCT05257551
TEMPUS Small Cell Lung Cancer OBSERVATIONAL STUDY (Sculptor)
Tempus AI·—·recruiting·n = 200
Small Cell Lung CancerObservation
brief summary
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
started
Jul 13, 2022
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Apr 2, 2026
official title
Tempus Small Cell Lung Cancer Observational Study (Sculptor): A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol